Tasly Pharmaceutical Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This Tasly Pharmaceutical Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP adds recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 21 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply the field and should not be read as evidence of absence.
Executive BD thesis
Tasly Pharmaceutical presents a practical BD-screening case because its returned pipeline contains 92 records and the deal search returned 4 transaction records. The lead returned asset is Zaoren Ningxin Pills, associated with a target not returned and Sleep Initiation and Maintenance Disorders, at Approved. The immediate objective is not to price a transaction; it is to identify where a focused outreach can unlock regional development, indication expansion, platform access, combination strategy, manufacturing leverage or non-dilutive capital.
The scan prioritizes assets with a named development owner and a traceable stage, then applies a conservative IP screen. A high-quality first meeting should ask for the current clinical/regulatory package, ownership chain, third-party licenses, patent-family schedule, CMC readiness and the specific rights the company is prepared to discuss.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | Zaoren Ningxin Pills | Tasly Pharmaceutical Group Co., Ltd. | Approved | Pipeline record: target not returned; Sleep Initiation and Maintenance Disorders. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | 天士力拟与神外所、北京仁诚生物签署合作协议，共同推进双靶点CAR-T项目 | Approved asset with undisclosed target exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 2 | Kunxinning Granules | Tasly Pharmaceutical Group Co., Ltd. | Approved | Pipeline record: target not returned; Menopausal syndrome. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | 天士力与Arbor签署终止协议，收回T89在美国的独家销售权 | Approved asset with undisclosed target exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 3 | Salvianolic Acid For Injection | Tianjin Tasly Pride Pharmaceutical Co., Ltd. | Approved | Pipeline record: target not returned; Brain Infarction. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | 华润三九医药股份有限公司关于收购天士力医药集团股份有限公司获国务院国资委批复的公告 | Approved asset with undisclosed target exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 4 | Qishen Yiqi Dropping Pills | Tasly Pharmaceutical Group Co., Ltd. | Approved | Pipeline record: POSTN; Chest Pain, Coronary Artery Disease, Blood Stasis. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | 天士力拟与神外所、北京仁诚生物签署合作协议，共同推进双靶点CAR-T项目 | Approved asset with POSTN exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 5 | Shaoma Zhijing Granules | Tasly Pharmaceutical Group Co., Ltd. | Approved | Pipeline record: target not returned; Tourette Syndrome. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | 天士力与Arbor签署终止协议，收回T89在美国的独家销售权 | Approved asset with undisclosed target exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
Shortlist interpretation. The top row should receive the fastest outreach, subject to confirmation that the returned owner and development stage remain current. Rows two through five are option-value workstreams: they can support a regional license, co-development, research collaboration, asset carve-out or structured option if the evidence package is sufficiently differentiated.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage. Those fields should be reconciled against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, safety narratives, manufacturing comparability and the latest investigator or regulator feedback.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across sources. A mismatch is itself a BD signal: it may reflect a recent transfer, dormant program, territory split, combination strategy or portfolio reprioritization. Any mismatch should be resolved before valuation or term-sheet design.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2026-03-19 | 天士力拟与神外所、北京仁诚生物签署合作协议，共同推进双靶点CAR-T项目 | Active | disclosed: false |
| 2026-02-07 | 天士力与Arbor签署终止协议，收回T89在美国的独家销售权 | Terminated | upfront_payment: 23; milestone_payment: 50; disclosed: true |
| 2024-08-04 | 华润三九医药股份有限公司关于收购天士力医药集团股份有限公司获国务院国资委批复的公告 | Completed | total_amount: 860.9645; disclosed: false |
The most relevant returned precedent is: 天士力拟与神外所、北京仁诚生物签署合作协议，共同推进双靶点CAR-T项目 (2026-03-19). Precedents should guide structure rather than mechanically determine price. Normalize for development stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones and change-of-control provisions. Where economics are undisclosed, the precedent still informs counterparties, strategic intent and preferred transaction form.
Financial capacity and partnering pressure
- Royalty Pharma plc - Prospectus(U.S. Stocks): Royalty Pharma plc - Prospectus(U.S. Stocks) Overview (1) Reflects cash deployed for royalty acquisitions from 2012 through Q2 2020 (2) I l d E i i i T ik d i J (2) Includes Epizyme equity investment; Tazverik not yet approved in Japan (3) Includes $16MM in R&D funding for Merck KGaA’s anti-IL 17 nanobody M1095, for which Royalty Pharma received a cash payment of 1.25x upon termination of development We seek to provide a “win-win” solution for our partners. In our transactions with our partners across the biopharmaceutical ecosystem, we aim to create favorable outcomes for all parties involved. We believe that our ability to provide mutually beneficial outcomes for our partners is important for the ongoing success of our business and for the maintenance of our leadership position within ou
- 永泰生物-B - 2022年度报告: 永泰生物-B - 2022年度报告 综合财务报表附注 i. 于2020年12月，本公司与Tasly Bioscience Fund Limited订立认购协议，内容有关认购于Tasly Bioscience Fund, L.P.（「Tasly Fund」）的有限合伙人权益。总认购金额为156.8百万港元。根据有限合伙协议的条款，Tasly Fund的初始期限为五年，各合 伙人将有权按彼等各自为该项目投资收购成本提供资金的缴足资本承担比例，分摊项目投资应占的损益。普通合伙人Tasly Bioscience Fund Limited对Tasly Fund的营运、投资事宜及其他相关事务的管理及控制拥有独家权力。 该投资根据国际财务报告准则第9号入账为按公允值计入损益的金融资产。总认购金额156,800,000港元（相当于人民币 131,969,000元）已于2020年12月31日支付。于2021年6月，Tasly Fund出资146,220,000港元（折合人民币119,769,000元）收购 Paul International Investment Limited （「Paul International」）100%的普通股，该公司持有一家位于大韩民国（「韩国」）的公司 （「目标A」）生物科技公司12.3%的普通股。 19. 按公允值计入损益的金融资产（续） 附注： （续） i. （续） 附注： （续） i. （续） Tasly Fund投资的公允值如下： 附注： 公允值变动以人民币呈列，亦包括将港元结余换算为人民币的汇兑影响。
Financial signals influence timing and leverage. Cash runway, operating burn, committed trial spend, debt covenants, shelf capacity and recent financings determine whether Tasly Pharmaceutical is more likely to pursue a broad license, regional partnership, cost-sharing collaboration, royalty financing or asset-level option. Figures returned from filings should be rechecked in the latest report before any negotiation.
Recent events and outreach timing
- No company-specific recent-news passage was returned. Confirm the latest clinical, regulatory, financing and leadership events directly with management.
Recent clinical, regulatory, financing, leadership and portfolio events can create a narrow outreach window. The BD team should map each event to a decision owner, an asset-level question and a proposed structure. Avoid generic “partnership interest” messages; lead with the specific program, territory, capability gap and evidence package that the prospective partner can improve.
IP and diligence risk screen
The default IP flag is medium until verified. Review composition-of-matter and sequence claims, method-of-use coverage, formulation and delivery patents, manufacturing know-how, platform licenses, university or government rights, prosecution status, patent-term adjustment/extension, oppositions, litigation, inventorship and freedom to operate. For biologics, cell/gene therapies and platform technologies, background IP and improvement-right provisions can be as important as the asset patents.
Commercial diligence should test addressable population, diagnosis and referral pathway, standard of care, competitor readouts, endpoint sensitivity, payer evidence needs, launch infrastructure and territory-specific regulatory requirements. The value of an asset is a function of the complete evidence package and executable rights—not development stage alone.
Recommended outreach sequence
- Contact the asset-level BD owner with a one-page rationale linked to the lead program and proposed territory or capability contribution.
- Request a non-confidential package covering current stage, dataset maturity, ownership, patent schedule, CMC status and partnering perimeter.
- Benchmark the returned precedents using stage-, modality- and territory-adjusted structures.
- Advance only programs with a coherent owner, evidence package, IP path and decision timeline into confidential diligence.
- Set explicit stop/go gates for data quality, freedom to operate, financing capacity and strategic fit.
Bottom line
Tasly Pharmaceutical merits targeted BD outreach where the returned pipeline and evidence package align with a partner’s geography, development capability or commercial infrastructure. The recommended next action is to validate Zaoren Ningxin Pills, confirm rights availability and test a structure calibrated to the company’s financial position and precedent set. The shortlist is designed to turn fragmented intelligence into an actionable owner-by-owner outreach plan.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
